Securities code: Beijing Scitop Bio-Tech Co.Ltd(300858) securities abbreviation: Beijing Scitop Bio-Tech Co.Ltd(300858) Announcement No.: 2022026 Beijing Scitop Bio-Tech Co.Ltd(300858)
Announcement on 2021 profit distribution plan
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Beijing Scitop Bio-Tech Co.Ltd(300858) (hereinafter referred to as “the company”) deliberated and adopted the proposal on profit distribution plan in 2021 at the 15th meeting of the second board of directors and the 14th meeting of the second board of supervisors held on April 24, 2021. The relevant information is hereby announced as follows: I. contents of profit distribution plan
Audited by Zhongshen Zhonghuan Certified Public Accountants (special general partnership), the net profit attributable to the shareholders of the parent company in the consolidated financial statements in 2021 was 10953937524 yuan, and the net profit of the parent company was 6905487926 yuan. According to the relevant provisions of the articles of association, the statutory surplus reserve of 690548793 yuan is withdrawn according to 10% of the net profit realized by the parent company in 2021. As of December 31, 2021, the undistributed profit in the audited consolidated financial statements was 25305250572 yuan, and the undistributed profit in the parent company’s statements was 18039499188 yuan. According to the principle of the lower of the distributable profits in the consolidated financial statements and the statements of the parent company, the distributable profits of the company were 18039499188 yuan as of December 31, 2021.
In accordance with the relevant provisions of the guidelines for the supervision of listed companies No. 3 – cash dividends of listed companies (revised in 2022), the company law of the people’s Republic of China and the articles of association, based on the company’s sustained and stable profitability, good financial position and good expectations for future development, in order to actively and reasonably return investors and share enterprise value, Based on the total share capital of 148531845 shares as of December 31, 2021, the company plans to distribute a cash dividend of RMB 5.00 (tax included) for every 10 shares to all shareholders, with a total cash dividend of RMB 7426592250 (tax included), and does not implement share distribution or conversion of capital reserve into share capital.
If the total share capital of the company changes due to equity incentive ownership and other reasons from the date when the board of directors deliberates and approves the profit distribution plan to the date of equity distribution registration, the company plans to adjust the total cash dividends accordingly according to the principle of unchanged distribution proportion. 2、 Relevant approval procedures and opinions
The above plans were deliberated and adopted at the 15th meeting of the second board of directors and the 14th meeting of the second board of supervisors held by the company on April 24, 2021. The independent directors of the company have expressed their independent opinions with explicit consent. This plan needs to be submitted to the 2021 annual general meeting of the company for deliberation.
1. Opinions of the board of directors
The board of Directors believes that the profit distribution plan proposed by the company for 2021 meets the needs of the company’s future operation and development, complies with the company law, the articles of association and other relevant systems and regulations, and has legitimacy, compliance and rationality. 2. Opinions of independent directors
The independent directors of the company reviewed the proposal on the profit distribution plan for 2021 and issued the following independent opinions:
The profit distribution plan for 2021 comprehensively considers the company’s normal operating conditions, future development and reasonable return of shareholders, which is in line with the actual situation of the company and the provisions of relevant laws and regulations and the articles of association. The profit distribution plan proposed by the company is conducive to all shareholders to share the company’s operating results, and matches the company’s operating performance and future development. There is no situation that damages the interests of the company and shareholders, especially small and medium-sized shareholders.
The independent directors of the company unanimously agreed to the company’s profit distribution plan for 2021 and agreed to submit the proposal to the company’s 2021 annual general meeting for deliberation.
3. Opinions of the board of supervisors
The board of supervisors believes that the profit distribution plan for 2021 complies with the relevant provisions of the company law and the articles of association, conforms to the current actual situation of the company, is conducive to the long-term development needs of the company, and does not harm the interests of shareholders. 3、 Risk tips
The profit distribution plan can only be implemented after being submitted to the 2021 annual general meeting of the company for deliberation and approval. Please invest rationally and pay attention to investment risks.
4、 Documents for future reference
1. Resolution of the 15th meeting of Beijing Scitop Bio-Tech Co.Ltd(300858) the second board of directors; 2. Resolution of the 14th meeting of Beijing Scitop Bio-Tech Co.Ltd(300858) the second board of supervisors; 3. Independent opinions of Beijing Scitop Bio-Tech Co.Ltd(300858) independent directors on matters related to the 15th meeting of the second board of directors.
It is hereby announced.
Beijing Scitop Bio-Tech Co.Ltd(300858) board of directors April 26, 2021
